Recursion advances neuroscience drug target with Genentech, reports Q2 2026 results and lowers 2026 cash expense guidance

Recursion Pharmaceuticals announced progress in its collaboration with Genentech by advancing the first neuroscience target into an early discovery program, demonstrating its AI platform's ability to find novel drug targets. The company also shared updates on its internal pipeline, including REC-4881 for Familial Adenomatous Polyposis and REC-7735 entering Phase 1/2 trials in late 2026. Financially, Recursion reported a net loss of $131 million for Q2 2026, with a cash position of $556.8 million and expects its cash runway to extend into early 2028. The company lowered its 2026 cash operating expense guidance to under $375 million, reflecting improved operational efficiencies.